Medical Industry Feature

Rise in Early-Onset Colon Cancer Being Studied Through Single-Cell Sequencing

Guest: Joel Gabre, M.D, MPH On this episode of Advances in Care, host Erin Welsh and Dr. Joel Gabre, a gastroenterologist at NewYork-Presbyterian and Columbia who specializes in cancer care, discuss the ongoing rise in colorectal cancer rates among younger individuals. Dr. Gabre lays out trends observed by the medical community in colorectal cancer rates, including the increasing likelihood by birth cohort for patients to develop this disease. He also talks about the main differences in colorectal cancer for patients from these different cohorts, most notably the location where cancers are likely to develop in the colon. In addition, Dr. Gabre shares some of the leading hypotheses for why colon cancer rates are rising in younger people, and how clinicians and researchers are focused on searching for answers to improve prevention and treatment options. He gets into the importance of the western diet in developing these forms of cancer and shares details about his team’s recent findings regarding changes at the cellular level that could be contributing to the accelerated growth of these cancers. Finally, Dr. Gabre speaks to his personal experiences as a gastroenterologist who has seen first-hand the rise in colon cancer rates among his younger patients. He shares a story of what …

2个月前

16分钟

Targeting PIK3CA Mutations in HR+/HER2- Breast Cancer: New Insights from ReDiscover

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD About 40 percent of patients with metastatic HR+/HER2- breast cancer have an activating mutation in the PIK3CA gene,1,2 which plays a key role not only in tumor growth, but also in driving resistance to endocrine therapy.3-5 And while there are several FDA-approved PI3K pathway-targeted agents for patients with PIK3CA tumor mutations,6-8 they come with challenges, like modest efficacy and on-pathway effects.9-12 Given this unmet need, the ReDiscover trial evaluated the investigational agent RLY-2608 in combination with fulvestrant in in patients with PIK3CA-mutated HR+/HER2- aBC previously treated with a CDK4/6 inhibitor.13 Joining Dr. Charles Turck to share updated safety and efficacy data from the trial is Dr. Sarah Sammons, a Senior Physician at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School in Boston. References: Vasan N, Cantley LC, Vasan N, Cantley LC. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nat Rev Clin Oncol. 2022;19(7):471-485. doi:10.1038/s41571-022-00633-1 Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi:10.1038/nature11412 Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor …

2个月前

15分钟

How GLP-1s Provide New Options to Manage Heart Disease

Guest: David Majure, M.D., MPH On this episode of Advances in Care, host Erin Welsh talks to Dr. David Majure, a cardiologist and heart failure specialist at NewYork-Presbyterian and Weill Cornell Medicine. Together, they discuss the rapid rise in GLP-1 research over the past few years, indicating new applications for these therapies to help a wide variety of patients. They explore how GLP-1s work on a molecular level and how using them to treat diabetes revealed other potential cardiovascular benefits. Dr. Majure highlights several recent studies that explore the effects of semaglutide and tirzepatide on patients with heart failure, particularly those with preserved ejection fraction. This new research demonstrates that GLP-1s can be an effective treatment beyond diabetes, helping with weight management and cardiovascular disease. Dr. Majure breaks down what effects doctors can expect to see in patients who are prescribed GLP-1s, including the difference in outcomes between semaglutide and tirzepatide. He also notes the potential risk factors, cautioning that while these medications are effective, the focus in addressing heart disease should always remain on prevention. © 2025 NewYork-Presbyterian

3个月前

20分钟

MMN in Practice: A Rare Motor Neuropathy Often Misdiagnosed

Host: Jennifer Caudle, DO Guest: Katie Beadon, MD, MASc, FRCPC Multifocal motor neuropathy (MMN) is a chronic, immune-mediated motor neuropathy that can mimic other neuromuscular disorders1-3 and is one of the few motor neuron disorders that is treatable.4 However, disease severity correlates with the length of time a patient remains untreated, which is why early recognition and treatment initiation is essential for preserving long-term motor function.5-6 Joining Dr. Jennifer Caudle to discuss the diagnosis and management of MMN is Dr. Katie Beadon, Co-Director of St. Paul’s Hospital Immunotherapy in Neurology Clinic and an Assistant Clinical Professor at the University of British Columbia in Vancouver. References: Guimarães-Costa R, Bombelli F, Léger JM. Multifocal motor neuropathy. Presse Med. 2013;42(6 Pt 2):e217-24. doi:10.1016/j.lpm.2013.01.057 Beadon K, Guimarães-Costa R, Léger JM. Multifocal motor neuropathy. Curr Opin Neurol. 2018;31(5):559-564. doi:10.1097/WCO.0000000000000605 Vlam L, van der Pol WL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol. 2011;8(1):48-58. doi:10.1038/nrneurol.2011.175 Yeh WZ, Dyck PJ, van den Berg LH, Kiernan MC, Taylor BV. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry. 2020;91(2):140-148. doi:10.1136/jnnp-2019-321532 Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. 2010;75(9):818-25. doi:10.1212/WNL.0b013e3181f0738e Van …

3个月前

13分钟

Pioneering a First in Robotic Liver Transplant

Guest: Juan P. Rocca, M.D., MHA On this episode of Advances in Care, host Erin Welsh hears from Dr. Juan P. Rocca, a transplant surgeon at NewYork-Presbyterian and Weill Cornell Medicine who recently led the first fully robotic liver transplant in New York. Dr. Rocca details the recent developments in robotic surgery at Weill Cornell Medicine’s Division of Liver Transplantation and Hepatobiliary Surgery, including an ongoing push to advance from laparoscopic and open surgical methods, and now to robotics. He explains why the robotic approach is optimal for complex liver surgeries and discusses how he and his team have been training to make robotic living donor hepatectomies a standard in their department. Then, Dr. Rocca breaks down the process of the liver transplant operation that became the first fully robotic execution in New York. He describes the most critical steps of the procedure, how it felt to achieve this milestone, and the example that he hopes to set for other institutions beyond NewYork-Presbyterian and Weill Cornell Medicine. © 2025 NewYork-Presbyterian

18分钟

Fibrodysplasia Ossificans Progressiva: Mechanism of Disease

Fibrodysplasia ossificans progressiva (FOP) is a severely disabling myopathy in which extraskeletal bone forms and accumulates over time within muscles and soft tissues.1,2 Here’s what we know so far about the mechanisms of heterotopic ossification in patients with FOP. References: Kaplan FS et al. Best Pract Res Clin Rheumatol 2008;22:191–205. Pignolo RJ et al. Orphanet J Rare Dis 2011;6:80. © 2025 Ipsen Biopharmaceuticals Inc. All rights reserved. ALLSC-US-001927 | August 2025

3分钟

QuickStart™ Myopia Minute: Talking to Parents About Treatment Options

Guest: Sheila Morrison, OD, MS, FSLS In this short video, Dr. Shelia Morrison explains how she introduces parents to myopia management by emphasizing that today's treatment options—like MiSight® 1 day—can both correct vision and slow myopia progression during critical growth periods. She highlights the importance of early intervention and presents daily disposable lenses as a safe, effective solution for active children.

QuickStart™ Myopia Minute: The Benefits, Comfort, and Safety of MiSight® 1 day

Guest: Eric Ritchey, OD, PhD, FAAO Listen to Dr. Eric Ritchey explain how he introduces MiSight® 1 day to parents—highlighting its safety, comfort, and dual benefits—and emphasizes the importance of daily disposables for hygiene and the long-term eye health advantages of managing myopia early in children.

1分钟

QuickStart™ Myopia Minute: Overcoming Barriers in Parent Conversations

Guest: Ariel Cerenzie, OD, FAAO, FSLS Dr. Ariel Cerenzie shares quick tips on how she communicates the urgency of myopia progression to parents and introduces MiSight® 1 day as a proactive solution. She explains that the lenses not only correct vision but also therapeutically slow myopia progression, offering a meaningful way to protect a child’s long-term eye health.

1分钟

Immune Imprinting and Vaccines: Rethinking the First Exposure to Influenza

Immune imprinting refers to how the immune system's first encounter with a virus, such as influenza, leaves a lasting imprint that shapes future immune responses.1,2 However, influenza vaccines may affect this process—particularly when egg-based ones are used. Tune in to learn about the impact of immune imprinting, the role that vaccines play in this process, and how switching to non-egg-based vaccines could help redirect immune responses and possibly create more effective defenses in people of all ages.3,4 References: King SM, Bryan SP, Hilchey SP, Wang J, Zand MS. First impressions matter: Immune imprinting and antibody cross-reactivity in influenza and SARS-CoV-2. Pathogens. 2023;12(2):169. doi:10.3390/pathogens12020169 Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses. J Immunol. 2019;202(2):335–340. doi:10.4049/jimmunol.1801149 Rockman S, Laurie K, Ong C, et al. Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness. Vaccines (Basel). 2022;11(1):52. doi:10.3390/vaccines11010052 Liu F, Gross FL, Jefferson SN, et al. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. J Clin Invest. 2021;131(8):e146138. doi:10.1172/JCI146138 USA-CRP-24-0038 July 2025

Adjuvanted vs High-Dose Influenza Vaccines: A Real-World Evidence Study

Host: Jennifer Caudle, DO Guest: Blen Girmay, MD Because standard-dose vaccines usually produce only modest immunogenic responses in people age 65 years and older, the Advisory Committee on Immunization Practices, as of June 2022, recommended this age group receive either an adjuvanted or higher-dose seasonal influenza vaccine.1,2,3 A pragmatic, head-to-head randomized study compared FLUAD and the high-dose influenza vaccine over the course of two influenza seasons.2 Joining Dr. Jennifer Caudle to discuss this study and its findings from the first season (2023-2024) is Dr. Blen Girmay, a Johns Hopkins fellowship-trained primary care geriatrician at Inova Health System in Fairfax, Virginia. References: Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021;15(6):813-823. Klein N. Oral presentation presented at: IDWeek 2024 Meeting; October 16-19, 2024. Los Angeles, CA. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. MMWR Recomm Rep. 2024;73(5):1-25.

15分钟

QuickStart™ Myopia Minute: Myopia Control and Early Treatment

Guest: Ashley Tucker, OD, FAAO, FSLS, Dipl ABO In this short video, Dr. Ashley Tucker shares how she talks to parents about myopia management, emphasizing that myopia is more than just blurry vision; it’s a progressive condition that can lead to serious eye health risks. She introduces MiSight® 1 day as a dual-purpose option that not only corrects vision, but also helps slow the progression of myopia in age-appropriate children.

5个月前

Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma

Guest: Mateo Mejia Saldarriaga, M.D. Mateo Mejia Saldarriaga, M.D., a hematologist/oncologist at NewYork-Presbyterian and Weill Cornell Medicine, explains how he and his team conducted a retrospective study that identified a biomarker to enhance treatment planning for BCMA CAR T-cell therapy in multiple myeloma. By measuring absolute lymphocyte count (ALC) through a routine CBC 15 days after a CAR T-cell therapy injection, they found patients with an ALC > 1,000 had a median progression-free survival (PFS) of 30 months whereas patients with an ALC ≤ 500 had a median PFS of 6 months. This new biomarker is now being leveraged to help doctors predict whether a patient is benefiting from treatment in as early as 15 days. © 2025 NewYork-Presbyterian

5个月前

3分钟

New 3D MRI Technology Offers Enhanced Visibility During Fibroid Surgery

Guest: Tamatha Fenster, M.D., M.S. Tamatha Fenster, M.D., M.S., gynecologic surgeon at NewYork-Presbyterian and director of innovation and technology at The Weill Cornell Medicine Fibroid and Adenomyosis Center, explains how her team has developed a new 3D MRI technology to enhance patient outcomes in fibroid surgery. The novel software, called smartHER MRI, renders a 3D image of a patient’s uterus to more accurately identify fibroids and their precise location, which can be used for both laparoscopic and robotic surgical procedures. In a pilot study analyzing smartHER MRI vs. 2D imaging, results demonstrated that surgeons who relied on traditional imaging had residual fibroids at the 6-month follow-up, while surgeons who used smartHER MRI had no residual fibroids with their patients. © 2025 NewYork-Presbyterian

5个月前

3分钟

A Landmark Surgery That Saved Three Children With One Heart

Guest: Andrew Goldstone, M.D., Ph.D. On this episode of Advances in Care, host Erin Welsh talks to Dr. Andrew Goldstone, pediatric cardiac surgeon at NewYork-Presbyterian and Columbia, about the groundbreaking heart transplant that saved the lives of three separate children. It was the first time doctors at NewYork-Presbyterian Morgan Stanley Children’s Hospital performed a split-root domino partial heart transplant. In this procedure, one child was transplanted with a new heart and their original heart was used to donate living pulmonary and aortic valves to two separate recipients in need. Dr. Goldstone, his colleague Dr. David Kalfa, and the rest of the team at NewYork-Presbyterian and Columbia had previous experience with a handful of domino partial heart transplants where one patient is transplanted with a new heart and another receives a valve from the explanted heart. Those experiences helped prepare for the split-root domino, which took nearly 24 hours of extremely coordinated care. In addition to their efforts to increase the number of domino heart transplants being done, physician-researchers at the institution are leading new studies that are also helping improve living valve procurement and storage, allowing more children to receive heart valves that will grow with them and require less surgeries. © 2025 …

6个月前

22分钟

Tailoring Approaches to Pediatric Rheumatic Disease: Best Practices for Long-Term Management

Guest: John Bridges, MD, MS For children with rheumatic diseases, early diagnosis, personalized care, and multidisciplinary collaboration are critical for optimal long-term management. Join Dr. John Bridges, Assistant Professor in the Division of Pediatric Rheumatology at the University of Alabama at Birmingham Heersink School of Medicine, as he explains how access, timing, and collaboration shape pediatric rheumatology care. Dr. Bridges presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.

8个月前

Newborn Gene Sequencing: Expanding Early Detection of Treatable Diseases

Guest: Joshua Milner, M.D. Guest: Eric Silver, M.D. Guest: Steven Lobritto, M.D. On this episode of Advances in Care, host Erin Welsh explores the story behind the GUARDIAN study, where thousands of newborn babies have been screened against rare disease by sequencing their genes, and looking for more conditions than any of the current standard screening panels. First, she hears from Dr. Jordan Orange, Physician-in-Chief at Morgan Stanley Children’s Hospital at NewYork-Presbyterian and Columbia, about why genetic testing is a promising way of not only catching treatable rare diseases in infants, but also expanding health equity and medical resources to marginalized populations. Erin also hears from Dr. Josh Milner, a pediatric immunologist who treated a patient with a rare form of SCID, or severe combined immune deficiency, also known as bubble boy disease that was detected in the GUARDIAN screening panel. SCID is a disease that typically occurs in 1 of 50,000 babies. But GUARDIAN caught two cases within the first 10,000 babies involved in the program, indicating that the rate of the disease might be higher than expected, and that the most accurate way to detect is through genetic screening. Dr. Steven Lobritto, a pediatric gastroenterologist, also weighs in on how genetic screening can help identify Wilson’s disease, a copper storage …

23分钟

From Diagnosis to Treatment: Challenges in Glioblastoma Care

Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

6分钟

Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data

Guest: Jennie Taylor, MD The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.

mIDH Gliomas Explained: Characteristics and Management Strategies

Guest: Jennie Taylor, MD Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires personalized strategies that consider resectability, histology, and long-term treatment impacts. Dr. Jennie Taylor, Assistant Professor of Neurology and Neurological Surgery at the University of California San Francisco, explains the complexities behind this type of tumor and implications for patient care. Dr. Taylor also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

4分钟

Decoding CIDP: Pathogenesis, Diagnosis, and Clinical Clues

Guest: Hans Katzberg, MD Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a complex immune-mediated condition affecting the peripheral nervous system. Join Dr. Hans Katzberg, Professor of Medicine at the University of Toronto, as he explains the pathophysiology behind CIDP, risk factors in disease development, and diagnostic strategies.

Personalized Care in Atopic Dermatitis: Addressing Patient-Specific Factors

Guest: Katrina Abuabara, MD, FAAD Phototherapy, biologics, and JAK inhibitors can all play a role in atopic dermatitis treatment, but it’s essential to consider patient-specific factors before choosing one of these options. Dr. Katrina Abuabara, Associate Professor of Dermatology at the University of California, San Francisco School of Medicine, explains how we should approach these decisions when caring for patients with atopic dermatitis. Dr. Abuabara also spoke on this topic at the 2025 American Academy of Dermatology Annual Meeting.

4分钟

Melanoma Treatment Breakthroughs: Improving Long-Term Survival

Guest: Vernon K. Sondak, MD Melanoma treatment has undergone a rapid evolution. Immunotherapy has doubled survival rates, and timing the use of these drugs around surgery has shown to be even more effective. Dr. Vernon Sondak explores how the fight against melanoma is stronger than ever with new therapeutic combinations and evolving treatment strategies. Dr. Sondak is the Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida.

Challenges in AI-Driven Dermatology: Understanding Current Limitations

Guest: Maria Hordinsky, MD, FAAD Artificial intelligence (AI) is reshaping dermatology care, but integrating it into clinical practice comes with challenges. Dr. Maria Hordinsky explores how clinics must adapt workflows and invest in new technologies to fully harness the potential for AI to drive better hair loss treatment. Dr. Hordinsky is the R. W. Goltz Professor and Vice Chair of Research in the Department of Dermatology at the University of Minnesota.

AI and Hair Loss: Measuring Progress with Data-Driven Insights

Guest: Maria Hordinsky, MD, FAAD From clinical research to direct patient care, dermatology tools powered by artificial intelligence (AI) present a new approach to hair loss treatment. Dr. Maria Hordinsky explains how virtual tattoo technology and at-home devices now provide measurable data, improving patient outcomes and allowing dermatologists to personalize treatment with precision. Dr. Hordinsky is the R. W. Goltz Professor and Vice Chair of Research in the Department of Dermatology at the University of Minnesota, and she spoke about this topic at the 2025 American Academy of Dermatology National Meeting.

4分钟

Advancing Cardiology and Heart Surgery Through a History of Collaboration

Guest: Craig Smith, M.D. On this episode of Advances in Care, host Erin Welsh and Dr. Craig Smith, Chair of the Department of Surgery and Surgeon-in-Chief at NewYork-Presbyterian and Columbia discuss the highlights of Dr. Smith’s 40+ year career as a cardiac surgeon and how the culture of Columbia has been a catalyst for innovation in cardiac care. Dr. Smith describes the excitement of helping to pioneer the institution’s heart transplant program in the 1980s, when it was just one of only three hospitals in the country practicing heart transplantation. Dr. Smith also explains how a unique collaboration with Columbia’s cardiology team led to the first of several groundbreaking trials, called PARTNER (Placement of AoRTic TraNscatheteR Valve), which paved the way for a monumental treatment for aortic stenosis — the most common heart valve disease that is lethal if left untreated. During the trial, Dr. Smith worked closely with Dr. Martin B. Leon, Professor of Medicine at Columbia University Irving Medical Center and Chief Innovation Officer and the Director of the Cardiovascular Data Science Center for the Division of Cardiology. Their findings elevated TAVR, or transcatheter aortic valve replacement, to eventually become the gold-standard for aortic stenosis patients at all levels of illness severity …

20分钟

Climate Change and Skin Health: Challenges and Adaptive Strategies

Guest: Eva Parker, MD, FAAD Rising temperatures, worsening air quality, and extreme weather events appear to be increasing the prevalence and severity of skin diseases. Dr. Eva Parker, Assistant Professor of Dermatology and Core Faculty at the Center for Biomedical Ethics and Society at Vanderbilt University Medical Center, shares strategies for dermatologists to improve climate literacy, reduce their carbon footprint, and educate patients on protecting their skin against climate-related impacts.

7分钟

CRSwNP: Exploring the Role of Nasal Epithelium and Epithelial Cytokines

Guest: Kathleen M. Buchheit, MD Guest: Joseph K. Han, MD Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a low quality of life and increased healthcare utilization,1,2 and patients often continue to have severe symptoms despite therapy.3 Understanding the role of underlying inflammatory pathways and epithelial dysfunction may help inform clinical decision making for these patients.3,4 In this program, Dr Kathleen Buchheit and Dr Joseph Han share their insights on the pathophysiology of CRSwNP and how unaddressed underlying inflammation may contribute to a variety of challenges for patients. Dr Buchheit is an Assistant Professor of Medicine at Harvard Medical School, specializing in Allergy and Immunology. Dr Han is a Professor of Otolaryngology, the Chief for the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, and the Chief of the Division of Allergy at Eastern Virginia Medical School in Norfolk, Virginia. References: Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10:1434-1453.e9 Bhattacharyya N, et al. Laryngoscope. 2019;129:1969-1975. van der Veen J, et al. Allergy. 2017;72:282-290. Laidlaw TM, et al. J Allergy Clin Immunol Pract. 2021;9:1133-1141. ©2024 Amgen and AstraZeneca. All rights reserved.US-96000 Last Updated 12/24

11个月前

15分钟

The Pathogenesis of Complement 3 Glomerulopathy (C3G)

Complement 3 glomerulopathy (C3G) is an ultra-rare kidney disease characterized by overactivation of the alternative complement pathway. This program provides insights into the pathogenesis of the disease. FA-11319389 12/24

11个月前